MaxCyte,
Inc.
("MaxCyte" or the "Company")
Total Voting
Rights
ROCKVILLE, MD, November 4,
2024: MaxCyte Inc., (Nasdaq: MXCT; LSE: MXCT), a
leading, cell-engineering focused company providing enabling
platform technologies to advance the discovery, development and
commercialization of next-generation cell-based therapeutics and
innovative bioprocessing applications, announces that pursuant to its block admission
facility, since September 30, it has issued 135,989 of common
stock, $0.01 par, of the Company ("Common Stock") in satisfaction
of the exercise of share options and/or vesting of restricted stock
units.
Total voting rights
As at October 31, 2024, the total
issued stock capital of the Company following the recent issue of
the new Common Stock is 105,434,869 shares of Common Stock.
Shareholders in the Company may use this figure as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, the stock capital of the Company.
For further information, please
contact:
|
|
MaxCyte Contacts:
US IR
Adviser
Gilmartin Group
David Deuchler, CFA
|
+1 415-937-5400
ir@maxcyte.com
|
|
|
|
Nominated Adviser and Joint
Corporate Broker
Panmure Liberum
Emma Earl / Freddy
Crossley
Corporate Broking
Rupert Dearden
|
+44 (0)20 7886 2500
|
|
|
|
UK IR
Adviser
ICR
Healthcare
Mary-Jane Elliott
Chris Welsh
|
+44 (0)203 709 5700
maxcyte@ICRHealthcare.com
|
|
|
|
|
|
|
|
|
|
|
About MaxCyte
At MaxCyte, we pursue cell
engineering excellence to maximize the potential of cells to
improve patients' lives. We have spent more than 20 years honing
our expertise by building best-in-class platforms, perfecting the
art of the transfection workflow, and venturing beyond today's
processes to innovate tomorrow's solutions. Our ExPERT™ platform,
which is based on our Flow Electroporation® technology, has been
designed to support the rapidly expanding cell therapy market and
can be utilized across the continuum of the high-growth cell
therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: four instruments, the ATx™,
STx™, GTx™ and VLx™; a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by a
robust worldwide intellectual property
portfolio. By providing our partners with
the right technology platform, as well as scientific, technical,
and regulatory support, we aim to guide them on their journey to
transform human health. Learn more
at maxcyte.com and follow us
on X and LinkedIn.
